While mutations affecting protein-coding regions have been examined across many cancers,
structural variants at the genome-wide level are still poorly defined. Through integrative …

Purpose The prevalence and features of treatment-emergent small-cell neuroendocrine prostate
cancer (t-SCNC) are not well characterized in the era of modern androgen receptor (AR)…

… Author contributions: Joshi J. Alumkal had full access to all the data in the study and
takes responsibility for the integrity of the data and the accuracy of the data analysis. …

… JJ Alumkal reports personal fees and other support from Astellas Pharma and other support
from Astellas Pharma during the conduct of the study; personal fees from Dendreon and …

Single-cell RNA sequencing (scRNA-seq) distinguishes cell types, states and lineages within
the context of heterogeneous tissues. However, current single-cell data cannot directly link …

Although DNA methylation is a key regulator of gene expression, the comprehensive
methylation landscape of metastatic cancer has never been defined. Through whole-genome …

Background: Real-time knowledge of the somatic genome can influence management of
patients with metastatic castration-resistant prostate cancer (mCRPC). While routine metastatic …

While programmed cell death 1 (PD-1) inhibitors have shown clear anti-tumor efficacy in
several solid tumors, prior results in men with metastatic castration resistant prostate cancer (…

Approximately 20% of metastatic prostate cancers harbor mutations in genes required for
DNA repair by homologous recombination repair (HRR) such as BRCA2. HRR defects confer …

Medical castration that interferes with androgen receptor (AR) function is the principal
treatment for advanced prostate cancer. However, clinical progression is universal, and tumors …